恩瑞格效果如何？

Deferasirox dispersible tablets () are mainly suitable for patients with iron accumulation due to long-term blood transfusion (such as those suffering from thalassemia or other rare anemias). It is suitable for children over two years old and adults. Enriga should not be used with other iron chelation treatments as the safety of such combined use has not been established. Enrig is contraindicated in patients with creatinine clearance <40mL/min or serum creatinine >2 times the upper limit of normal for the corresponding age; patients with poor general condition, high-risk myelodysplastic syndrome (MDS) or advanced malignant tumors; patients with platelet count <50x109/L.

Dosage and usage of deferasirox dispersible tablets: (Starting dose) The recommended starting daily dose of deferasirox dispersible tablets is 20 mg/kg. For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (i.e., more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered. For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered.

So what is the effect of Enrig?

According to a retrospective study in Italy, 42.7% of patients achieved a hematological response and reduced the need for blood transfusions after receiving DFO or deferasirox chelation therapy. There may be a dynamic, bidirectional regulatory mechanism between erythropoiesis and iron overload. On the one hand, ineffective erythropoiesis can lead to increased intestinal iron absorption through reduced hepcidin secretion by the liver. On the other hand, chelation treatment of iron overload can improve erythropoiesis, increase hemoglobin levels, and reduce clinical blood transfusions.

Deferasirox dispersible tablets are oral medicines that are convenient to take once a day. Adverse reactions are mainly gastrointestinal reactions, rashes, liver and kidney damage, etc. However, the incidence of these is not high. Even if they occur, they can generally be alleviated by adjusting the drug dosage and taking method. However, the disadvantage of deferasirox is that it is relatively expensive and is not included in the medical insurance reimbursement list.

However, a generic version of deferasirox has now been launched in India. This drug is produced by cipla in India. Its efficacy is the same as deferasirox, but the price is much cheaper. It is very suitable for patients who pursue a higher quality of life. However, the drug is not marketed in the country. If necessary, please consult Medical Companion Travel for purchasing methods.